Bullish on immuno-oncology, BMS returns Erbitux to Lilly
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has returned North American rights to the anticancer Erbitux (cetuximab) to Lilly after a collaboration of 14 years initiated with ImClone, which was acquired by Lilly. BMS cited its "prioritized opportunities" in immuno-oncology.